摘要
目的探讨泮托拉唑与瑞巴派特联合应用于慢性糜烂性胃炎患者中的效果。方法研究对象来自于2014年12月至2018年12月我院收治的慢性糜烂性胃炎病例,共计178例。采用随机数表法分将178例研究对象进行组别划分,分为对照组89例与研究组89例。对照组应用泮托拉唑治疗,研究组在此基础上联合应用瑞巴派特治疗。通过症状观察评价两组治疗前与治疗8w后临床症状的改善情况,以及前列腺素E2(PGE2)、丙二醛(MDA)的变化。同时,观察并记录两组治疗期间的药物不良反应。结果治疗8周研究组嗳气、胃部疼痛、腹胀不适与反酸评分低于对照组(P<0.05)。治疗8周后研究组PGE2水平高于对照组(P<0.05),MDA水平低于对照组(P<0.05)。研究组治疗期间药物不良反应发生率2.25%与对照组2.25%对无明显差异(P>0.05)。结论慢性糜烂性胃炎患者采用泮托拉唑联合瑞巴派特治疗,疗效确切,可以有效改善患者的临床症状,纠正胃黏膜损伤,安全可靠,值得临床推广。
Objective To investigate the effect of pantoprazole combined with rebamipide in the treatment of chronic erosive gastritis.Methods 178 patients with chronic erosive gastritis admitted to our hospital from December 2014 to December 2018 were selected as the study subjects,and randomly divided into control group and research group with 89 cases in each group.The control group was treated with pantoprazole,and the study group was combined with the application of rebamipide.The improvement of clinical symptoms and the changes of prostaglandin E2(PGE2)and malondialdehyde(MDA)were evaluated by symptom observation before and after treatment.At the same time,adverse drug reactions during treatment were observed and recorded.Results After treatment,the scores of belching,stomach pain,abdominal distension,discomfort and acid regurgitation in the study group were lower than those in the control group(P<0.05).After treatment,the level of PGE2 was higher than that of control group(P<0.05),and the level of MDA was lower than that of control group(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the control group 2.25%and the control group 2.25%(P>0.05).Conclusion Pantoprazole combined with ribapacit is effective in treating chronic erosive gastritis.It can effectively improve clinical symptoms and correct gastric mucosal injury.It is safe and reliable and worthy of clinical promotion.
作者
周红连
管敬来
ZHOU Hong-lian;GUAN Jing-lai(Department of Gastroenterology,Renhe Hospital,Beijing 102600,China)
出处
《中国医药指南》
2020年第15期92-93,共2页
Guide of China Medicine
